The American Course on Drug Development and Regulatory Science and the US National Institutes of Health held a workshop on cell-based immunotherapy on 22 January 2019.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
06 August 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
References
Mezher, M. Regulatory Affairs Professional Society https://www.raps.org/news-and-articles/news-articles/2019/1/gottlieb-marks-detail-plans-to-advance-developmen?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=Focus%20on%20Biotech%3A%20January (2019).
Sadelain, M. Cell 171, 1471 (2017).
Maude, S. L. et al. N. Engl. J. Med. 378, 439–448 (2018).
Maude, S. L. et al. N. Engl. J. Med. 371, 1507–1517 (2014).
Grupp, S.A. 60th American Society of Hematology Annual Meeting, abstr. 895 (2018).
Cherkasova, E., Weisman, Q. & Childs, R. W. Front. Oncol. 3, 243 (2013).
Takahashi, Y. et al. J. Clin. Invest. 118, 1099–1109 (2008).
Porter, D. L. et al. Sci. Transl. Med. 7, 303ra139 (2015).
Lee, D. W. et al. Biol. Blood Marrow Transplant. 25, 625–638 (2019).
Maude, S. L., Barrett, D., Teachey, D. T. & Grupp, S. A. Cancer J. 20, 119–122 (2014).
Teachey, D. T. et al. Cancer Discov. 6, 664–679 (2016).
Grupp, S. A. et al. N. Engl. J. Med. 368, 1509–1518 (2013).
Vodnala, S.K. et al. Science 363, (2019).
Rosenberg, S. A. & Restifo, N. P. Science 348, 62–68 (2015).
Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Nat. Rev. Cancer 12, 671–684 (2012).
Gautam, S. et al. Nat. Immunol. 20, 337–349 (2019).
Sade-Feldman, M. et al. Cell 175, 998–1013.e20 (2018).
Eyquem, J. et al. Nature 543, 113–117 (2017).
Ellis, J. Hum. Gene Ther. 16, 1241–1246 (2005).
Rivière, I., Dunbar, C. E. & Sadelain, M. Blood 119, 1107–1116 (2012).
von Kalle, C., Deichmann, A. & Schmidt, M. Hum. Gene Ther. 25, 475–481 (2014).
Xu, Z., Park, Y., Zhen, B. & Zhu, B. Stat. Med. 37, 4589–4609 (2018).
Xu, Z., Zhen, B., Park, Y. & Zhu, B. Stat. Med. 36, 592–605 (2017).
Tran, E., Robbins, P. F. & Rosenberg, S. A. Nat. Immunol. 18, 255–262 (2017).
Cafri, G. et al. Nat. Commun. 10, 449 (2019).
Flying machines which do not fly. The New York Times https://newspaperarchive.com/new-york-times-oct-09-1903-p-6/ (1903).
Wright, O. Diaries and Notebooks: Orville Wright. Library of Congress https://www.loc.gov/item/wright002238/ (1903).
Acknowledgements
We thank all the speakers, panelists, and organizers who made this workshop possible: Greg Campbell (GCStat Consulting), Cathy Cantilena (NIH), Natalie DeWitt (Accendo Scientific and NDA Partners), David DiGiusto (Semma Therapeutics), Jaikumar Duraiswamy (OTAT, FDA), Ellen Feigal (NDA Partners and Arizona State University), Thomas Fellner (Lonza Pharma & Biotech), Brett Giroir (US Department of Health and Human Services) Stephan Grupp (CHOP), Jaime Kenyon (American Course on Drug Development and Regulatory Science and the University of California, San Francisco), Harvey Klein (NIH), Telba Irony (CBER, FDA), Roger Kurlander (CBER, FDA), Crystal Mackall (Stanford University), Jorge-Mansilla-Soto (Memorial Sloan Kettering Cancer Center), Peter Marks (CBER, FDA), Carl Peck (NDA Partners and the University of California, San Francisco), Nicholas Restifo (NCI), Steven Rosenberg (NCI), Nirali Shah (NCI), David Stroncek (NIH), and Allen Wensky (OTAT, FDA, CBER). The full list of speakers and ‘slide decks’ for most of the presentations are on the website of the University of California, San Francisco, American Course on Drug Development and Regulatory Science (https://pharm.ucsf.edu/acdrs/events/acdrs-nih-workshop-cell-based-immunotherapy-bench-bedside-beyond).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.G.F. directs the Biologics Practice at NDA Partners and is on the board of directors of the ARM Foundation for Cell and Gene Medicine.
Rights and permissions
About this article
Cite this article
Feigal, E.G., DeWitt, N.D., Cantilena, C. et al. At the end of the beginning: immunotherapies as living drugs. Nat Immunol 20, 955–962 (2019). https://doi.org/10.1038/s41590-019-0452-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-019-0452-8